As Lilly pauses much of its research owing to the coronavirus pandemic, Vantage takes a look at an estimate of the cash committed to ongoing clinical studies. Clue: it’s…
Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
A Vantage analysis of FDA decisions expected in the next month and how the ongoing Covid-19 pandemic could affect these.
The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.
As the company prepares to host its first investor day in over a decade the focus falls on underappreciated in-house assets.
The CS1 approach to treating multiple myeloma was once thought capable of matching CD38, but that train left the station some time ago.
Despite Astrazeneca stacking the odds in its favour Imfinzi’s Danube trial, in first-line bladder cancer, reads out negatively.
A private Belgian biotech reckons Tigit is the new PD-1, a view Roche’s progress could validate.